Related Experiment Video

Updated: Jul 23, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.1K

Long non-coding RNAs in non-small cell lung cancer: implications for EGFR-TKI resistance

Detian Liu1, Xiaolin Lu2, Wentao Huang1

  • 1Department of Thoracic Surgery, Xiangya Hospital of Central South University, Changsha, Hunan, China.

Frontiers in Genetics
|July 17, 2023
PubMed

Insights

Long non-coding RNAs (lncRNAs) are key players in non-small cell lung cancer (NSCLC) developing resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs). Understanding lncRNA mechanisms is crucial for overcoming treatment resistance in NSCLC patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality worldwide.
  • Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) have improved outcomes for EGFR-mutated NSCLC.
  • Acquired resistance to EGFR-TKIs remains a significant clinical challenge, leading to disease progression.

Purpose of the Study:

  • To review the critical role of long non-coding RNAs (lncRNAs) in mediating EGFR-TKI resistance in NSCLC.
  • To elucidate the diverse molecular mechanisms by which lncRNAs contribute to treatment resistance.
  • To discuss the clinical implications and future directions of lncRNA research in overcoming NSCLC resistance.

Main Methods:

  • Comprehensive literature review of studies investigating lncRNAs and EGFR-TKI resistance in NSCLC.
  • Analysis of identified lncRNAs' functions and mechanisms of action.
  • Synthesis of information on signaling pathways, cellular processes, and epigenetic modifications involved.

Main Results:

  • lncRNAs modulate EGFR-TKI resistance through various mechanisms, including activation of bypass signaling pathways.
  • Phenotypic transformation, intercellular communication within the tumor microenvironment, and ceRNA networks are influenced by lncRNAs.
  • Epigenetic modifications mediated by lncRNAs also contribute significantly to resistance development.

Conclusions:

  • lncRNAs are pivotal regulators of EGFR-TKI resistance in NSCLC, offering potential therapeutic targets.
  • Understanding lncRNA-driven resistance mechanisms is essential for developing novel treatment strategies.
  • Further research into lncRNAs holds promise for improving clinical outcomes for NSCLC patients.
Keywords:
drug resistanceepidermal growth factor receptor (EGFR)long non-coding RNAs (lncRNA)non-small cell lung cancer (NSCLC)tyrosine kinase inhibitors (TKIs)

More Related Videos

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
11.6K